Topic Hub
4 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 4 of 4 clinical reviews.
A detailed regulatory guide to alprostadil compounding under FDA sections 503A and 503B, covering Caverject and MUSE approval history, trimix legality, outsourcing facility rules, and state-level pharmacy requirements.
Read clinical reviewA comprehensive review of FDA label changes for alprostadil (Caverject, MUSE, Edex) from 2020 through 2026, covering safety revisions, post-market surveillance data, and clinical guidance for prescribers.
Read clinical reviewA clinical review of alprostadil's FDA history, current label, post-market safety data, and next-generation delivery systems in development for erectile dysfunction.
Read clinical reviewA detailed comparison of how the FDA and EMA regulate alprostadil (Caverject, MUSE, Vitaros), including approval timelines, labeled indications, safety monitoring, and post-market requirements.
Read clinical review